m+Medelevator.RU
← Поиск публикаций
World neurosurgery · 2016

LVIS Stent Versus Enterprise Stent for the Treatment of Unruptured Intracranial Aneurysms.

Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ge Huijian, Lv Xianli, Yang Xinjian, He Hongwei, Jin Hengwei, Li Youxiang

Аннотация

OBJECTIVE: This retrospective study compared clinical and angiographic outcomes between LVIS and Enterprise stents.

MATERIALS AND METHODS: From November 2014 to December 2015, total 190 patients with 208 unruptured intracranial aneurysms were coiled assisted by LVIS and Enterprise stents. Procedure-related complications, clinical outcomes, and angiographic results were analyzed retrospectively.

RESULTS: A total of 92 patients with 96 aneurysms received LVIS stents and 98 patients with 112 aneurysms were treated with Enterprise stents. Procedure-related complications occurred in 10.9% of patients (2 hemorrhagic events and 8 thromboembolic events) in the LVIS stents group whereas 16.3% (1 hemorrhage, 1 mass effect, and 14 thromboembolic events) in the Enterprise stents group. No statistical significant differences in thromboembolic (P = 0.263), hemorrhagic complications (P = 0.611), and favorable clinical outcomes (modified Rankin Scores of 0-2) (P = 0.379) were found between 2 groups. A greater initial complete or near-complete obliteration was found in the LVIS stents group compared with the Enterprise stents group (96.9% vs. 88.4%, P = 0.034). Larger aneurysm size (P = 0.048) was an independent predictor of procedure-related complications in univariate analysis.

CONCLUSIONS: Compared with Enterprise stents, LVIS stents may achieve greater complete or near-complete occlusion rate. There was no significant difference in procedural-related complications and clinical outcomes between LVIS and Enterprise stents.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты